Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already indicate readOnlyHint=true, openWorldHint=true, idempotentHint=true, destructiveHint=false. The description adds substantial behavioral context: data sources (SEC EDGAR/XBRL for companies, FAERS for drugs), sorting by primary metric, and citation URIs. No contradictions.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is informative but slightly verbose, especially the opening list of synonyms. However, each sentence adds value, and the structure is logical: purpose, usage preference, type-specific details, output format.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given no output schema, the description adequately explains return values (paired data + citation URIs). It covers both entity types comprehensively, including edge cases like off-calendar fiscal years. The tool's complexity (2-5 entities, multiple data sources) is well addressed.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%, and the description enriches parameter meaning. For 'type', it explains the different data sources and metrics. For 'values', it specifies tickers/CIKs for companies and drug names, with explicit min/max count guidance.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool provides side-by-side comparison of 2-5 companies or drugs, with specific verb phrases like 'compare', 'rank', 'head-to-head'. It distinguishes itself from sequential single-pack lookups, highlighting its unique value.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly says 'ALWAYS PREFER over sequential single-pack lookups when comparing entities', providing strong usage guidance. It also explains when to use type='company' vs. type='drug', but could better exclude cases where this tool is not appropriate.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.7/5.0
Disambiguation1/5

The tool set has severe overlap: ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, discover_tools, and suggest_questions all serve similar query/discovery purposes, and multiple polymarket tools (polymarket_edges, polymarket_arbitrage, bet_research) overlap heavily in finding betting opportunities. An agent would struggle to select among these without deep familiarity, especially when ask_pipeworx and ask_pipeworx_beta are currently identical.

Naming Consistency2/5

Individual families are internally consistent (ca_procurement_*, polymarket_*, pipeworx_*), but the server as a whole mixes domain-prefixed snake_case, bare verb phrases (ask_pipeworx, bet_research), and descriptive noun phrases (entity_profile, recent_changes). More importantly, the vast majority of tool names have nothing to do with the server's stated 'Ca Procurement' identity, so the naming fails to signal a coherent tool set.

Tool Count2/5

36 tools is well past the 25+ threshold for 'too many,' and over 85% of them (31 tools) are unrelated to California procurement—they cover general data lookup, prediction markets, npm packages, and memory storage. A scoped CA procurement server would reasonably have 5–8 tools; this is a general-purpose data platform wearing a procurement label.

Completeness3/5

The five relevant ca_procurement_* tools cover the main read-side query patterns well: award search, commodity rankings, department profiles, supplier aggregation, and top suppliers. However, the surface lacks contract/award detail retrieval by ID, solicitation or RFP search, and any vendor registration or contract lifecycle data, leaving notable gaps for a procurement-focused tool set.